All In Biotech

Drug Trial Radar · NCT02953821

Acthar Gel for Active Systemic Lupus Erythematosus (SLE)

A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids

Last checked: Nov 20, 2026Latest source record: Aug 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 172 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

172

Actual

Start

Dec 16, 2016

Primary completion

Jul 31, 2019

Study completion Oct 25, 2019

Sponsor

Lead sponsor
MallinckrodtIndustry
Sponsor type
Industry
First posted
Nov 3, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is to study Acthar Gel in participants with active systemic lupus erythematosus (SLE). The doctor will assign eligible patients to one of two groups (like flipping a coin). Participants will receive the treatment assigned to their group for 24 weeks: * Acthar Gel * Placebo Gel, which looks like Acthar Gel, but has no medicine in it. The doctor or his staff will take measurements and ask questions to: * see how well the gel is working * see how safe it is for patients with SLE

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • Acthar GelDrug

    1 mL (80 Units) given by a shot under the skin (via subcutaneous injection)

  • Placebo GelDrug

    1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Physician's Global Assessment (PGA)Time frame: Baseline, Week 16, Week 24
  2. British Isles Lupus Assessment Group 2004 (BILAG 2004)Time frame: Baseline, Week 16, Week 24
  3. Number of Participants With at Least a 4 Point Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K)Time frame: Week 16, Week 24

Locations

39 sites in 5 countries. Site status is shown where the registry gives one.

  • C.V. Mehta MD Medical Corporation

    Hemet, California

  • Inland Rheumatology Clinical Trials

    Upland, California

  • Center for Rheumatology Immunology and Arthritis

    Fort Lauderdale, Florida

  • San Marcus Research Clinic

    Miami, Florida

  • Advanced Pharma CR

    Miami, Florida

  • Millennium Research

    Ormond Beach, Florida

  • Office of George Timothy Kelly MD

    Las Vegas, Nevada

  • NewYork-Presbyterian Columbia University Medical Center

    New York, New York

  • DJL Clinical Research

    Charlotte, North Carolina

  • Paramount Medical Research & Consulting

    Middleburg Heights, Ohio

  • Arthritis & Rheumatology Center of Oklahoma

    Oklahoma City, Oklahoma

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • West Tennessee Physicians' Alliance

    Jackson, Tennessee

  • Office of Ramesh C. Gupta, MD

    Memphis, Tennessee

  • Accurate Clinical Research

    Houston, Texas

  • Sun Research Institute

    San Antonio, Texas

  • Aprillus Asistencia e Investigación

    Buenos Aires, Argentina

  • Consultorios Médicos Dr. Catalán Pellet

    Buenos Aires, Argentina

  • Centro Medico Privado de Reumatología

    San Miguel de Tucumán, Argentina

  • Biomedica Research Group

    Santiago, Chile

  • IBIOMED Research Unit Aguascalientes

    Aguascalientes, Mexico

  • Centro Especializado en Investigación Clínica

    Boca del Río, Mexico

  • Phylasis Clinicas Research S de RL de CV

    Cuautitlán Izcalli, Mexico

  • Instituto de Investigaciones Aplicadas a la Neurociencia A.C.

    Durango, Mexico

  • Centro Peninsular de Investigacion Clinica S.C.P.

    Mérida, Mexico

  • Köhler and Milstein Research

    Mérida, Mexico

  • Consultorio de Reumatología

    México, Mexico

  • Centro Integral de Reumatologia

    México, Mexico

  • Unidad de Investigación de las Enfermedades Reumáticas

    Mexico City, Mexico

  • Accelerium Clinical Research

    Monterrey, Mexico

  • Centro de Estudios Clínicos y Especialidades Médicas

    Monterrey, Mexico

  • SMIQ

    Querétaro, Mexico

  • Centro de Alta Especialidad en Reumatologia e Investigación del Potosí, SC

    San Luis Potosí City, Mexico

  • Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.

    Zapopan, Mexico

  • Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde

    Guadalajara, Jalisco, Mexico

  • Investigaciones Clinicas S.A.C. del Instituto de Ginecologia y Reproduccion

    Lima, Peru

  • Clinica Vesalio

    San Borja, Peru

  • Hospital de Apoyo Maria Auxiliadora

    San Juán de Miraflores, Peru

  • Hospital Nacional Cayetano Heredia

    San Martín de Porres, Peru

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.